AKTX: Akari Therapeutics PLC Price to Sales

Symbol and logo of brand Akari Therapeutics plc (AKTX)

Akari Therapeutics (AKTX) relies on global express temperature-controlled delivery of biomaterials to develop immunotherapy. The volatility of the P/S ratio reflects market expectations, with the mark indicating the current state. Meanwhile, Akari Therapeutics faces capital requirements and clinical risks, utilizing a virtual management model via external CROs to conduct the final stages of trials.

Price-to-Revenue Ratio: Akari Therapeutics (AKTX) for 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Akari Therapeutics (AKTX)

General company analysis:AKTX, Akari Therapeutics plc
Signature product of Akari Therapeutics, Plc

Searching for assets with a high margin of safety requires a deep assessment of market value relative to actual earnings. The P/S multiple compares a business's total capitalization with its annual revenue, determining how much an investor pays per unit of sales. For Akari Therapeutics (AKTX), this calculation is critical, as the risk of competition from biotech behemoths in the rare disease niche could distort the valuation. By analyzing the price-to-sales multiple on GURU.Markets, one can identify whether the asset is overbought and the likelihood of a correction.

Who Akari Therapeutics competes with

argenx - Market Cap to Revenue Ratio|P/S Multiple BNTX (biontech.de)|Abivax Corp (ABVX) - Price to Sales|ADMA Corp - P/S Multiple|Price-to-Sales Ratio PTGX|Immunovant Inc (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|GRFS (Grifols Biemat) - P/S Multiple|P/S Multiple Adaptive Biotechnologies Inc.|Price-to-Revenue Ratio Celldex Therapeutics (CLDX)|Price-to-Revenue Coefficient auriniapharma.com|Price-to-Revenue Ratio BioCryst Pharmaceuticals BCRX|Market Capitalization-to-Revenue Ratio VERA|Dianthus Pharma - P/S Multiple|PHVS - P/S Multiple|ABCL: P/S Multiple|TRML (Tourmaline Bio, Inc.) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Intrexon|PHAR - Price-to-Revenue Multiple|P/S Multiple NKTR|Price-to-Revenue Ratio UPB (Upstream Bio Corp)|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|Price-to-Revenue Coefficient immunome.com (IMNM)|Gossamer Bio Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (KalVista Pharmaceuticals, Inc.)|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharmaceuticals Inc|Market Cap to Revenue SVRA|Market Cap to Revenue Rigel Pharmaceuticals (RIGL)|P/S Multiple ANAB|ATXS - Price to Sales|Price-to-Revenue Ratio enGene Corp ENGN|Price-to-Revenue Coefficient RAPT Therapeutics, Inc. (RAPT)|Aerovate - P/S Multiple|ACRS - P/S Multiple|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|Price to Sales Tiziana Life Sciences Ltd. (TLSA)|Market Cap to Revenue CABA|Ventyx Biosciences (VTYX) - Price-to-Revenue Coefficient|P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Market Capitalization-to-Revenue Ratio|P/S Multiple ELDN (eledon.com)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Sales Ratio ZURA|ATYR: P/S Multiple|Adagene Corp (ADAG) - P/S Multiple|Market Cap to Revenue IMA|Shattuck Labs, Inc. - Price-to-Sales Ratio|Price-to-Revenue Ratio Equillium Inc (EQ)|P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Revenue Ratio Immunic, Inc. IMUX|P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Revenue Ratio|XFOR: Price-to-Revenue Ratio|ACET: P/S Multiple|CELU - Price-to-Revenue Coefficient|Price-to-Revenue Ratio inmunebio.com|Market Cap to Revenue Ratio BRNS (barinthusbio.com)|P/S Multiple KZR|P/S Multiple SAB Biotherapeutics, Inc (SABS)|P/S Multiple ENLV (Enlivex Therapeutics Ltd)|q32bio.com - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|edesabiotech.com (EDSA) - Market Cap to Revenue|IBIO: P/S Multiple|CARM - Price-to-Revenue Coefficient|Market Cap to Revenue XTLB|Market Cap to Revenue boltbio.com (BOLT)|Price-to-Revenue Ratio HCW Biologics Inc (HCWB)|P/S Multiple Aptevo Therapeutics, Inc. (APVO)|Price-to-Revenue Ratio aimimmuno.com AIM|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio Corporation - P/S Multiple|XORTX Corp (XRTX) - Market Cap to Revenue|HIND (Vyome Holdings Inc.) - Market Cap to Revenue|revbiosciences.com (REVB) - P/S Multiple|INDP (Indaptus Corp) - P/S Multiple|Market Cap to Revenue Scinai Immunotherapeutics Ltd (SCNI)|Price-to-Revenue Ratio CalciMedica Inc (CALI)|AFMD (Affimed NV) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos Inc.)|P/S Multiple HOOKIPA HOOK|IGMS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ITOS (iTeos)|OCEA: P/S Multiple|TCBP (TC BioPharm Ltd) - Price-to-Revenue Ratio|THRD (Third Harmonic Bio Inc) - P/S Multiple